context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million... | text | 2.1 | sharesItemType | text: <entity> 2.1 </entity> <entity type> sharesItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shar... | us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued |
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million... | text | 238 | monetaryItemType | text: <entity> 238 </entity> <entity type> monetaryItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million sh... | us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued |
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million... | text | 192 | monetaryItemType | text: <entity> 192 </entity> <entity type> monetaryItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million sh... | us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued |
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million... | text | 91 | monetaryItemType | text: <entity> 91 </entity> <entity type> monetaryItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million sha... | us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued |
During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest we... | text | 280 | monetaryItemType | text: <entity> 280 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling fina... | us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries |
During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest we... | text | 228 | monetaryItemType | text: <entity> 228 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling fina... | us-gaap:AdjustmentsToAdditionalPaidInCapitalOther |
During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest we... | text | 52 | monetaryItemType | text: <entity> 52 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling finan... | us-gaap:MinorityInterestDecreaseFromRedemptions |
As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. </context> | us-gaap:CapitalExpendituresIncurredButNotYetPaid |
As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. | text | 3.8 | monetaryItemType | text: <entity> 3.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. </context> | us-gaap:CapitalExpendituresIncurredButNotYetPaid |
As of December 31, 2024, letters of credit totaling approximately $ 816 million, which were executed in the normal course of business and support several financing arrangements and payment obligations to third parties, were outstanding. | text | 816 | monetaryItemType | text: <entity> 816 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, letters of credit totaling approximately $ 816 million, which were executed in the normal course of business and support several financing arrangements and payment obligations to third parties, were outstanding... | us-gaap:LettersOfCreditOutstandingAmount |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 16.7 | monetaryItemType | text: <entity> 16.7 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms... | us-gaap:RecordedUnconditionalPurchaseObligation |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 6.2 | monetaryItemType | text: <entity> 6.2 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms ... | us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 5.5 | monetaryItemType | text: <entity> 5.5 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms ... | us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 3.1 | monetaryItemType | text: <entity> 3.1 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms ... | us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms ... | us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 291 | monetaryItemType | text: <entity> 291 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms ... | us-gaap:RecordedUnconditionalPurchaseObligationDueInFifthYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to p... | text | 363 | monetaryItemType | text: <entity> 363 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms ... | us-gaap:RecordedUnconditionalPurchaseObligationDueAfterFifthYear |
Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. | text | 617 | monetaryItemType | text: <entity> 617 </entity> <entity type> monetaryItemType </entity type> <context> Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. | text | 592 | monetaryItemType | text: <entity> 592 </entity> <entity type> monetaryItemType </entity type> <context> Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. | text | 436 | monetaryItemType | text: <entity> 436 </entity> <entity type> monetaryItemType </entity type> <context> Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 bi... | us-gaap:MarketingAndAdvertisingExpense |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 bi... | us-gaap:MarketingAndAdvertisingExpense |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 bi... | us-gaap:MarketingAndAdvertisingExpense |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affect... | text | 797 | monetaryItemType | text: <entity> 797 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the... | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affect... | text | 462 | monetaryItemType | text: <entity> 462 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the... | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affect... | text | 556 | monetaryItemType | text: <entity> 556 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the... | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 242 | monetaryItemType | text: <entity> 242 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </cont... | us-gaap:Revenues |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 358 | monetaryItemType | text: <entity> 358 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </cont... | us-gaap:Revenues |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 297 | monetaryItemType | text: <entity> 297 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </cont... | us-gaap:Revenues |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 43 | monetaryItemType | text: <entity> 43 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </conte... | us-gaap:CostOfGoodsAndServicesSold |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 109 | monetaryItemType | text: <entity> 109 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </cont... | us-gaap:CostOfGoodsAndServicesSold |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </conte... | us-gaap:CostOfGoodsAndServicesSold |
BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing ... | text | 62.50 | perShareItemType | text: <entity> 62.50 </entity> <entity type> perShareItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was fu... | us-gaap:BusinessAcquisitionSharePrice |
BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing ... | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was fund... | us-gaap:PaymentsToAcquireBusinessesGross |
BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing ... | text | 3.6 | monetaryItemType | text: <entity> 3.6 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was fund... | us-gaap:BusinessCombinationConsiderationTransferred1 |
(a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. | text | 159 | monetaryItemType | text: <entity> 159 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. </co... | us-gaap:PaymentsToAcquireBusinessesGross |
(a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. | text | 115 | monetaryItemType | text: <entity> 115 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. </co... | us-gaap:PaymentsToAcquireBusinessesGross |
Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuation method. Goodwill resulted primarily from the recognition of deferred tax liabilit... | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuat... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuation method. Goodwill resulted primarily from the recognition of deferred tax liabilit... | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuat... | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati com... | text | 58.00 | perShareItemType | text: <entity> 58.00 </entity> <entity type> perShareItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders al... | us-gaap:BusinessAcquisitionSharePrice |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati com... | text | 4.8 | monetaryItemType | text: <entity> 4.8 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also... | us-gaap:PaymentsToAcquireBusinessesGross |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati com... | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also... | us-gaap:BusinessCombinationConsiderationTransferred1 |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati com... | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also... | us-gaap:BusinessCombinationContingentConsiderationLiability |
(a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. | text | 60 | monetaryItemType | text: <entity> 60 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
(a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. | text | 54 | monetaryItemType | text: <entity> 54 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( | text | 148 | monetaryItemType | text: <entity> 148 </entity> <entity type> monetaryItemType </entity type> <context> Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory |
Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( | text | 640 | monetaryItemType | text: <entity> 640 </entity> <entity type> monetaryItemType </entity type> <context> Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
) and $ 3.5 billion of indefinite-lived IPRD assets. The estimated fair value of both definite-lived Acquired marketed product rights and indefinite-lived IPRD assets was determined using an income approach valuation method. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> ) and $ 3.5 billion of indefinite-lived IPRD assets. The estimated fair value of both definite-lived Acquired marketed product rights and indefinite-lived IPRD assets was determined using an income approach valuation method. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
In 2023, BMS acquired the rights to Orum's ORM-6151 program, which is currently in Phase I clinical development. ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. The consideration included an upfront payment of $ 1... | text | 80 | monetaryItemType | text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS acquired the rights to Orum's ORM-6151 program, which is currently in Phase I clinical development. ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader for the treatment of patients with acute myeloid leukemia or high-... | us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration |
In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS r... | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the comm... | us-gaap:PaymentsToAcquireBusinessesGross |
In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS r... | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the comm... | us-gaap:BusinessCombinationConsiderationTransferred1 |
(b) Includes pension settlement charges of $ 119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan. | text | 119 | monetaryItemType | text: <entity> 119 </entity> <entity type> monetaryItemType </entity type> <context> (b) Includes pension settlement charges of $ 119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan. </context> | us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 |
As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $ 322 million of expense that was included in Other (income)/expense, net in 2023. The expense was determined based on the closing price of the... | text | 322 | monetaryItemType | text: <entity> 322 </entity> <entity type> monetaryItemType </entity type> <context> As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $ 322 million of expense that was included in Other (incom... | us-gaap:LitigationSettlementExpense |
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements ... | text | 560 | monetaryItemType | text: <entity> 560 </entity> <entity type> monetaryItemType </entity type> <context> In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to B... | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements ... | text | 418 | monetaryItemType | text: <entity> 418 </entity> <entity type> monetaryItemType </entity type> <context> In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to B... | us-gaap:ProceedsFromLegalSettlements |
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements ... | text | 384 | monetaryItemType | text: <entity> 384 </entity> <entity type> monetaryItemType </entity type> <context> In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to B... | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory appro... | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provide... | us-gaap:ProceedsFromLegalSettlements |
In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory appro... | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provid... | us-gaap:ProceedsFromLegalSettlements |
In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s str... | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to en... | us-gaap:RestructuringAndRelatedCostExpectedCost1 |
In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s str... | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to en... | us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 |
Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). For these plans, the remaining charges of approximately $ 250 million consist p... | text | 250 | monetaryItemType | text: <entity> 250 </entity> <entity type> monetaryItemType </entity type> <context> Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2... | us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 |
Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. </context> | us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment |
Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. | text | 12.1 | monetaryItemType | text: <entity> 12.1 </entity> <entity type> monetaryItemType </entity type> <context> Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. </context> | us-gaap:IncomeTaxReconciliationNondeductibleExpense |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. | text | 644 | monetaryItemType | text: <entity> 644 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit,... | us-gaap:IncomeTaxReconciliationTaxSettlements |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. | text | 89 | monetaryItemType | text: <entity> 89 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, ... | us-gaap:IncomeTaxReconciliationTaxSettlements |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. | text | 522 | monetaryItemType | text: <entity> 522 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit,... | us-gaap:IncomeTaxReconciliationTaxSettlements |
Puerto Rico imposed an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax was recognized in Cost of products sold when the intra-entity sale occurred. For U.S. income tax purposes, the excise tax was not deductible but resulted in foreign tax credits that... | text | 10.5 | percentItemType | text: <entity> 10.5 </entity> <entity type> percentItemType </entity type> <context> Puerto Rico imposed an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax was recognized in Cost of products sold when the intra-entity sale occurred. For U.S. income tax... | us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential |
The U.S. Federal net operating loss carryforwards were $ 2.0 billion at December 31, 2024. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue Code. The net operating loss carryforwards expire in varying amounts beginning in 2024... | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. Federal net operating loss carryforwards were $ 2.0 billion at December 31, 2024. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue C... | us-gaap:OperatingLossCarryforwards |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal defer... | text | 929 | monetaryItemType | text: <entity> 929 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal defer... | text | 294 | monetaryItemType | text: <entity> 294 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal defer... | text | 453 | monetaryItemType | text: <entity> 453 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal defer... | text | 182 | monetaryItemType | text: <entity> 182 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million i... | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining... | us-gaap:IncomeTaxesPaidNet |
Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million i... | text | 4.3 | monetaryItemType | text: <entity> 4.3 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining... | us-gaap:IncomeTaxesPaidNet |
Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million i... | text | 5.4 | monetaryItemType | text: <entity> 5.4 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining... | us-gaap:IncomeTaxesPaidNet |
It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benef... | text | 360 | monetaryItemType | text: <entity> 360 </entity> <entity type> monetaryItemType </entity type> <context> It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement ... | us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benef... | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement ... | us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
The total number of potential shares of common stock excluded from the diluted earnings per share computation because of the antidilutive impact was 38 million in 2024 and not material in 2023 and 2022. | text | 38 | sharesItemType | text: <entity> 38 </entity> <entity type> sharesItemType </entity type> <context> The total number of potential shares of common stock excluded from the diluted earnings per share computation because of the antidilutive impact was 38 million in 2024 and not material in 2023 and 2022. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respectively. | text | 220 | monetaryItemType | text: <entity> 220 </entity> <entity type> monetaryItemType </entity type> <context> Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respective... | us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount |
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respectively. | text | 119 | monetaryItemType | text: <entity> 119 </entity> <entity type> monetaryItemType </entity type> <context> Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respective... | us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount |
into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 billion for Japanese yen contracts as of December 31, 2024. | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 bi... | us-gaap:DerivativeNotionalAmount |
into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 billion for Japanese yen contracts as of December 31, 2024. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 bi... | us-gaap:DerivativeNotionalAmount |
BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. ... | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of t... | us-gaap:DerivativeNotionalAmount |
In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senio... | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were d... | us-gaap:DerivativeNotionalAmount |
In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senio... | text | 131 | monetaryItemType | text: <entity> 131 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were d... | us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax |
Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offse... | text | 892 | monetaryItemType | text: <entity> 892 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes ar... | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offse... | text | 498 | monetaryItemType | text: <entity> 498 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes ar... | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offse... | text | 345 | monetaryItemType | text: <entity> 345 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes ar... | us-gaap:DerivativeNotionalAmount |
a) In 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of € 375 million, and the amount represents the effective portion of foreign exchange loss on the remeasurement of the debt. | text | 375 | monetaryItemType | text: <entity> 375 </entity> <entity type> monetaryItemType </entity type> <context> a) In 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of € 375 million, and the amount represents the effective portion of foreign exchange loss on the remeasurement of the debt. </contex... | us-gaap:DebtInstrumentFaceAmount |
As of December 31, 2024, under the commercial paper program, BMS could issue up to $ 7.0 billion of unsecured notes, with maturities of not more than 365 days from the date of issuance. Of this amount, $ 3.0 billion was issued and repaid during the year ended December 31, 2024. In January 2025, the maximum amount of co... | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, under the commercial paper program, BMS could issue up to $ 7.0 billion of unsecured notes, with maturities of not more than 365 days from the date of issuance. Of this amount, $ 3.0 billion was issued and repa... | us-gaap:ProceedsFromIssuanceOfCommercialPaper |
(a) As of December 31, 2024, floating rate equals SOFR+ 0.49 %. | text | 0.49 | percentItemType | text: <entity> 0.49 </entity> <entity type> percentItemType </entity type> <context> (a) As of December 31, 2024, floating rate equals SOFR+ 0.49 %. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approxi... | text | 45.3 | monetaryItemType | text: <entity> 45.3 </entity> <entity type> monetaryItemType </entity type> <context> The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the s... | us-gaap:DebtInstrumentFairValue |
The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approxi... | text | 36.7 | monetaryItemType | text: <entity> 36.7 </entity> <entity type> monetaryItemType </entity type> <context> The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the s... | us-gaap:DebtInstrumentFairValue |
In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: | text | 13.0 | monetaryItemType | text: <entity> 13.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: </context> | us-gaap:DebtInstrumentFaceAmount |
In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: | text | 12.9 | monetaryItemType | text: <entity> 12.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: </context> | us-gaap:DeferredFinanceCostsNet |
The Company used the net proceeds from this offering to partially fund the acquisitions of RayzeBio and Karuna (see "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information) and used the remaining net proceeds for general corporate purposes. In connection with the issuance of the ... | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company used the net proceeds from this offering to partially fund the acquisitions of RayzeBio and Karuna (see "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information) and used the remainin... | us-gaap:DebtInstrumentFaceAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of ... | text | 4.5 | monetaryItemType | text: <entity> 4.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corpo... | us-gaap:DebtInstrumentCarryingAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of ... | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corpo... | us-gaap:DebtInstrumentCarryingAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of ... | text | 5.9 | monetaryItemType | text: <entity> 5.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corpo... | us-gaap:ProceedsFromDebtNetOfIssuanceCosts |
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt ... | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 mi... | us-gaap:ExtinguishmentOfDebtAmount |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.